IPO - Profile


We are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 7,500,000 Positive High 28.12%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 18 Mar, 2021

Offer 19 Mar, 2021

Look Ahead

Lock Up Expiry Sep 19, 2021

IPO Terms

Offer Price $17.00
Offer Size 7M

Market Sentiments

Stock Price